WHO ICTRP trial
A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and…
EUCTR2020-000876-40-BE · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2020-000876-40-BE |
|---|---|
| Public title | A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN intermediate-risk, stage II-III rectAl cancer |
| Scientific title | A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN intermediate-risk, stage II-III rectAl cancer - REGINA |
| Primary sponsor | Institut Jules Bordet |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Belgium |
| Conditions | rectal cancer MedDRA version: 21.0 Level: PT Classification code 10038049 Term: Rectal cancer stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.0 Level: PT… |
| Interventions | Trade Name: stivarga Pharmaceutical Form: Tablet CAS Number: 755037-03-7 Other descriptive name: REGORAFENIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Product Name: nivolumab Pharmaceutical… |
| Registration date | Nov 23, 2020 |
| Target size | 66 |
| Secondary IDs | IJB-REGINA-2020 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: